In aim­ing to by­pass CRISPR's de­liv­ery is­sues, one start­up eyes the gene edit­ing Spot­light

Much hype has been grant­ed to­ward a co­hort of CRISPR gene edit­ing biotechs, in­clud­ing the epony­mous start­up found­ed by No­bel Prize win­ner Em­manuelle Char­p­en­tier. But one such com­pa­ny has stayed rel­a­tive­ly qui­et, al­beit for a sub­tle se­ries A emer­gence in No­vem­ber 2020.

Now, the GV-backed start­up is ready for the spot­light with a new round of fi­nanc­ing. Yes, the biotech is named Spot­light Ther­a­peu­tics, and the 28-em­ploy­ee com­pa­ny wants to skirt the de­liv­ery is­sues in­grained in the typ­i­cal CRISPR path of vi­ral and nanopar­ti­cle trans­porta­tion. The biotech will have to cre­ate its own spot­light to edge in­to the gene-edit­ing space via in vi­vo cell-tar­get­ed de­liv­ery.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER